Seohui Jang

Seohui Jang

Auto-generated profile, based on publicly available information

Seohui Jang

Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Republic of Korea; Department of Biomedical Science, CHA University, Pocheon, Republic of Korea

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2026 in JHEP Reports
Verified
Journal Article
Open access
SJSeohui Jang
Seohui Jang
JSJihun Song
Jihun Song
EKEun Seok Kang
Eun Seok Kang
SCSangwook Cheon
Sangwook Cheon
TKTaeho Kwak
Taeho Kwak
SJSeogsong Jeong
Seogsong Jeong
Changes in the amount of alcohol consumption among individuals with steatotic liver disease (SLD) result in shifts between the phenotypes of metabolic dysfunction-associated SLD (MASLD), MASLD with increased alcohol intake (MetALD), and alcohol-related liver disease (ALD). Yet, real-world evidence on how these shifts affect the incidence of liver-related events (LREs) remains scarce. Therefore, we aimed to evaluate the impact of these dynamic subtype shifts on the risk of LREs. In the nationwide cohort, 2,795,409 Korean adults who completed two consecutive biennial health examinations (2009-2010 and 2011-2012) were classified as MASLD, MetALD, or ALD at both assessments. Subtype transitions were determined based on fatty liver index-defined hepatic steatosis, cardiometabolic risk factors, and alcohol consumption. Participants were retrospectively followed from 2013 to 2022 for the occurrence of LREs, ascertained through diagnostic codes. Adjusted subdistribution hazard ratios (aSHRs) were calculated using the Fine-Gray model, accounting for death as a competing event. The shift in SLD subtype from baseline to follow-up was closely aligned with corresponding changes in LRE risk. Individuals who remained in MASLD at both time points exhibited the lowest risk of composite LREs during the 9-year follow-up. In contrast, shifts from MASLD or MetALD to ALD were associated with the greatest escalation in LRE risk (MASLD-to-ALD: aSHR, 1.92 [95% CI, 1.83-2.02]; MetALD-to-ALD: aSHR, 1.27 [95% CI, 1.19-1.35]). Conversely, transitions toward MASLD were linked to substantial reductions in risk (MetALD-to-MASLD: aSHR, 0.89 [95% CI, 0.85-0.94]; ALD-to-MASLD: aSHR, 0.78 [95% CI, 0.73-0.83]). Because dynamic changes in SLD subtypes strongly influence liver-related outcomes, regular reassessment of SLD classification is essential for timely and appropriate clinical management. In this large, nationwide cohort of over 2.7 million Korean adults, we demonstrated marked heterogeneity in long-term liver outcomes according to dynamic steatotic liver disease subtype trajectories, providing strong scientific justification for monitoring disease evolution rather than relying on static classifications. These findings underscore the prognostic value of both alcohol intake reduction and metabolic risk management, highlighting the importance of integrated strategies for patients with hepatic steatosis. Clinicians and researchers should recognize the need for comprehensive care models that combine behavioral interventions such as alcohol screening, counseling, and referral to addiction services with pharmacological management of metabolic risk factors. Particularly, patients with MetALD and those with ALD represent highly vulnerable subgroups, underscoring the need for tailored strategies that address both alcohol use and metabolic dysfunction.

1 January 2026 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YKYihyun Kim
Yihyun Kim
SJSeohui Jang
Seohui Jang
HKHee-Ju Kang
Hee-Ju Kang
JKJae-Min Kim
Jae-Min Kim
EKEun Seok Kang
Eun Seok Kang
HwaMin LeeHwaMin Lee
HwaMin Lee
Kim Y, et al. J Korean Med Sci. 2026 Dec;41:e314. https://doi.org/10.3346/jkms.2026.41.e314

4 August 2026 in Journal of the American Heart Association
Verified
Journal Article
Closed access
SCSangwook Cheon
Sangwook Cheon
SJSeohui Jang
Seohui Jang
EKEun Seok Kang
Eun Seok Kang
JSJihun Song
Jihun Song
JKJaewon Khil
Jaewon Khil
SJSeogsong Jeong
Seogsong Jeong
Background: Older adults with metabolic dysfunction–associated steatotic liver disease have elevated cardiovascular disease (CVD) risk, yet conventional models, such as the Framingham Risk Score, rely on linear assumptions and were developed for younger populations. Nonlinear machine learning approaches may improve risk prediction in this high‐risk group. Methods: Using Korean National Health Insurance Service data, this population‐based cohort study followed up 67 575 adults, aged ≥65 years, with metabolic dysfunction–associated steatotic liver disease (assessed 2009–2010) for incident CVD, coronary heart disease, and stroke from 2011 to 2019. Cox proportional hazards (CoxPH) models identified time‐to‐event predictors, whereas an extreme gradient boosting (XGBoost)–based survival model explored nonlinear associations and predicted 9‐year CVD risk. Results: Both CoxPH and XGBoost models outperformed the Framingham Risk Score, with CoxPH showing slightly better discrimination than XGBoost in the validation sets. The 2 models identified broadly similar leading predictors. For coronary heart disease, both identified Charlson comorbidity index, antiplatelet agent use, and serum creatinine among the most important predictors. In the CoxPH model, the Charlson comorbidity index had the highest explained relative risk (0.031), and the XGBoost model also ranked Charlson comorbidity index first by Shapley Additive Explanations value (0.159). For stroke, both models identified age, Charlson comorbidity index, and antiplatelet agent use as the top 3 predictors, with age ranked first (explained relative risk, 0.065; Shapley Additive Explanations, 0.239). Similar findings were observed for total CVD. Conclusions: In older adults with metabolic dysfunction–associated steatotic liver disease, CoxPH and survival XGBoost showed similar predictive performance and identified key predictors not emphasized in traditional models, like the Framingham Risk Score. These findings underscore limitations of applying younger‐population–based tools to older adults with metabolic dysfunction–associated steatotic liver disease and support the development of tailored CVD risk models.